Concord Biotech Limited Stocks

Established in 1984 and headquartered in Ahmedabad, India, Concord Biotech Limited operates as a biopharmaceutical enterprise focused on the discovery, development, production, and global commercialization of pharmaceutical goods. A core component of its offerings comprises fermentation-derived active pharmaceutical ingredients (APIs) applied across various critical medical fields. These include immunosuppressive agents (such as tacrolimus, mycophenolate mofetil, mycophenolate sodium, cyclosporine, sirolimus, and pimecrolimus), anti-bacterial compounds (like mupirocin, mupirocin calcium, vancomycin hydrochloride, and teicoplanin), oncology treatments (including temsirolimus, everolimus, romidepsin, mitomycin, midostaurin, and dactinomycin), and antifungal medications (such as anidulafungin, caspofungi, and micafungin sodium). Additionally, the company supplies other specialized APIs like lovastatin and pravastatin sodium. Concord Biotech further augments its services by providing contract research and manufacturing solutions (CRAMS), particularly emphasizing fermentation and semi-synthesis capabilities.